- Home
- SES vs AURA Comparison
SES vs AURA Comparison
Compare SES & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SES
- AURA
- Stock Information
- Founded
- SES 2012
- AURA 2007
- Country
- SES United States
- AURA United States
- Employees
- SES N/A
- AURA N/A
- Industry
- SES Auto Parts:O.E.M.
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- SES Consumer Discretionary
- AURA Health Care
- Exchange
- SES Nasdaq
- AURA Nasdaq
- Market Cap
- SES 384.0M
- AURA 396.8M
- IPO Year
- SES N/A
- AURA 2021
- Fundamental
- Price
- SES $2.75
- AURA $5.76
- Analyst Decision
- SES Buy
- AURA Strong Buy
- Analyst Count
- SES 1
- AURA 7
- Target Price
- SES $2.00
- AURA $22.29
- AVG Volume (30 Days)
- SES 15.8M
- AURA 283.0K
- Earning Date
- SES 10-30-2025
- AURA 11-11-2025
- Dividend Yield
- SES N/A
- AURA N/A
- EPS Growth
- SES N/A
- AURA N/A
- EPS
- SES N/A
- AURA N/A
- Revenue
- SES $11,360,000.00
- AURA N/A
- Revenue This Year
- SES $883.92
- AURA N/A
- Revenue Next Year
- SES $159.98
- AURA N/A
- P/E Ratio
- SES N/A
- AURA N/A
- Revenue Growth
- SES N/A
- AURA N/A
- 52 Week Low
- SES $0.20
- AURA $4.35
- 52 Week High
- SES $3.05
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- SES 83.76
- AURA 37.10
- Support Level
- SES $1.57
- AURA $5.93
- Resistance Level
- SES $2.01
- AURA $6.28
- Average True Range (ATR)
- SES 0.25
- AURA 0.26
- MACD
- SES 0.09
- AURA -0.02
- Stochastic Oscillator
- SES 82.51
- AURA 5.22
About SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.